Endoscopic papillectomy is a recognized treatment for ampullary lesions, including the rare subtype of laterally spreading lesions (LSLs) of the papilla of Vater. LSLs are characterized by their extensive involvement of the duodenal mucosa, making them distinct and more challenging to treat compared to non-LSL ampullary lesions.
Endoscopic papillectomy is a recognized treatment for ampullary lesions, including the rare subtype of laterally spreading lesions (LSLs) of the papilla of Vater. LSLs are characterized by their extensive involvement of the duodenal mucosa, making them distinct and more challenging to treat compared to non-LSL ampullary lesions. A recent study compared the outcomes of endoscopic papillectomy for LSLs versus non-LSLs in matched patient cohorts.
The study included 1422 endoscopic papillectomies, with a subset of 232 matched patients (116 LSLs and 116 non-LSLs) based on factors such as age, sex, co-morbidities, and histologic subtype. The primary outcome, complete resection (R0) after the first intervention, was significantly lower in the LSL group (54.3%) compared to the non-LSL group (69.0%). However, after repeated endoscopic interventions, technical success rates were similar for both groups (82.8%).
Despite achieving comparable technical success, LSLs exhibited a significantly higher recurrence rate (41.3%) compared to non-LSLs (15.0%) during a median follow-up of 22 months. Additionally, disease-free survival rates at 1 and 3 years were notably lower in the LSL group (61.1% and 44.0%, respectively) compared to the non-LSL group (86.1% and 81.6%, respectively). Complication rates, however, were not significantly different between the two groups (32.8% for LSLs vs. 26.7% for non-LSLs).
In conclusion, endoscopic papillectomy is a safe and viable option for treating LSLs of the papilla of Vater, but it often requires multiple interventions to achieve complete resection. The higher recurrence rates associated with LSLs highlight the need for vigilant post-procedure surveillance and follow-up care.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.